Similar articles

• Five-year change of prevalence and risk factors for infection and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary hospital in North China.

  Li Y, Li J, Hu T, Hu J, Song N, Zhang Y, Chen Y. Li Y, et al. Antimicrob Resist Infect Control. 2020 Jun 1;9(1):79. doi: 10.1186/s13756-020-00728-3. Antimicrob Resist Infect Control. 2020. PMID: 32487221 Free PMC article.
• Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections in a Chinese Children's Hospital: Predominance of New Delhi Metallo-β-Lactamase-1.

  Dong F, Zhang Y, Yao K, Lu J, Guo L, Lyu S, Yang Y, Wang Y, Zheng H, Song W, Liu G. Dong F, et al. Microb Drug Resist. 2018 Mar;24(2):154-160. doi: 10.1089/mdr.2017.0031. Epub 2017 Jun 8. Microb Drug Resist. 2018. PMID: 28594635
• Outbreak of KPC-producing Klebsiella pneumoniae ST15 strains in a Chinese tertiary hospital: resistance and virulence analyses.

  Huang J, Chen X, Yang J, Zhao Y, Shi Y, Ding H, Zhao X, Xu J, Wu R, Zhao Z. Huang J, et al. J Med Microbiol. 2022 Feb;71(2). doi: 10.1099/jmm.0.001494. J Med Microbiol. 2022. PMID: 35156610
• Predictors of mortality in patients with carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis and a systematic review.

  Qian Y, Bi Y, Liu S, Li X, Dong S, Ju M. Qian Y, et al. Ann Palliat Med. 2021 Jul;10(7):7340-7350. doi: 10.21037/apm-21-338. Epub 2021 Jul 13. Ann Palliat Med. 2021. PMID: 34263631
• Cost-effectiveness of antimicrobial treatment for inpatients with carbapenem-resistant Klebsiella pneumoniae infection: a systematic review of economic evidence.

  Dos Santos WM, Aromataris E, Secoli SR, Matuoka JY. Dos Santos WM, et al. JBI Database System Rev Implement Rep. 2019 Dec;17(12):2417-2451. doi: 10.11124/JBISRIR-D-18-00019. JBI Database System Rev Implement Rep. 2019. PMID: 31821188